Cypherpunk posts $39.39 million Q2 profit as ZEC holdings generate $46 million unrealized gain

News Editor

2026-08-12 11:22:14

Cypherpunk Technologies, a ZEC treasury company listed on Nasdaq under the ticker CYPH, reported net income of $39.39 million for the second quarter of 2026, equal to diluted earnings per share of $0.18. In the same period a year earlier, the company posted a net loss of $16.64 million. The company also recorded an operating loss of $4.69 million, while research and development expense fell to $0.2 million from $10.54 million, which it attributed to the completion of clinical trials. General and administrative expense rose by $2.75 million year over year to $4.49 million, mainly due to higher stock-based compensation. As of June 30, cash stood at $7.6 million. Cypherpunk said the main driver of quarterly profit was a $46 million non-cash unrealized gain tied to its ZEC holdings, as the token’s price rose from $243.35 to $400.09 during the quarter. As of Aug. 11, 2026, the company held 323,394.38 ZEC at an average cost of about $341.83, representing roughly 1.92% of circulating supply and a market value of about $129 million.

Cypherpunk Technologies (Nasdaq: CYPH), a ZEC treasury company, reported second-quarter 2026 net income of $39.39 million, or $0.18 in diluted earnings per share, according to a company update cited by BlockBeats on Aug. 12. A year earlier, the company posted a net loss of $16.64 million.

The company recorded an operating loss of $4.69 million in the quarter. Research and development expense fell to $0.2 million from $10.54 million in the same period last year, which the company said was mainly due to the completion of clinical trials. General and administrative expense reached $4.49 million, up $2.75 million year over year, mainly because of increased stock-based compensation. Cash balance stood at $7.6 million as of June 30.

ZEC holdings drove quarterly profit

Cypherpunk said the main source of profit in the second quarter was a non-cash unrealized gain tied to its ZEC position. During the quarter, the price of ZEC rose from $243.35 to $400.09, resulting in a $46 million unrealized gain.

As of Aug. 11, 2026, the company held a total of 323,394.38 ZEC at an average cost of about $341.83. The position accounted for roughly 1.92% of ZEC’s circulating supply and was valued at about $129 million.

Advisory appointment and subsidiary update

On the business side, Cypherpunk appointed Valar Group founder Dev Ojha as an adviser. The company said Valar Group focuses on Zcash network development and research, and has led development of the high-performance full-node software Zakura and the Ironwood shielded pool.

Cypherpunk also said its subsidiary Leap Therapeutics had aligned with the U.S. Food and Drug Administration on the Phase 3 trial design for sirexatamab, a DKK1 monoclonal antibody. The therapy received Fast Track designation from the FDA in May 2026 for the treatment of second-line metastatic colorectal cancer patients with high DKK1 expression.

The company said it has also launched a strategic process to evaluate the best path for advancing sirexatamab development, either through standalone financing or in partnership with a collaborator.

This article was originally published by Bit.Fan. For more cryptocurrency news and market insights, visit www.bit.fan.

470

Disclaimer:

The market information, project data, and third-party content displayed on this platform are for industry information sharing only and do not constitute any form of investment advice or return commitment.

Cryptocurrency trading carries high risks. Users should fully assess their risk tolerance and make independent decisions. All profits, losses, and legal responsibilities are borne by the users themselves.